MRNA

Moderna, Inc. MRNA

NasdaqLarge CapHealthcare

13F Pro quality score

Rank #2,757 of 2,925

Why it scores 20Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$145.00M

Quarter to Jun 30

Net income

$-782.00M

Quarter to Jun 30

Free cash flow

$-563.00M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$22.36B total
FMR LLC
$3.63B+13.5%
BlackRock, Inc.
$2.14B+3.3%
VANGUARD CAPITAL MANAGEMENT LLC
$1.63B+1.5%
Capital World Investors
$1.56B+19.1%
BAILLIE GIFFORD & CO
$1.28B-8.9%
STATE STREET CORP
$1.10B+5.8%
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.09B-0.2%
GEODE CAPITAL MANAGEMENT, LLC
$678.82M+2.9%
MORGAN STANLEY
$667.95M+12.6%
Theleme Partners LLP
$564.27M+0.1%
TWO SIGMA INVESTMENTS, LP
$503.76M-20.8%
Invesco Ltd.
$404.79M+20.8%
PRICE T ROWE ASSOCIATES INC /MD/
$391.44M+656.8%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$338.87M+2.2%
GOLDMAN SACHS GROUP INC
$327.18M-29.3%
Flagship Pioneering Inc.
$324.39M0.0%
UBS Group AG
$312.56M+1.3%
BNP PARIBAS FINANCIAL MARKETS
$306.53M+1.4%
NORGES BANK
$211.92M--
NORTHERN TRUST CORP
$209.06M+1.1%
BANQUE PICTET & CIE SA
$189.04M-1.8%
DIMENSIONAL FUND ADVISORS LP
$172.88M+15.8%
WELLINGTON MANAGEMENT GROUP LLP
$172.38M+4.4%
Merck & Co., Inc.
$161.64M0.0%
CITIGROUP INC
$151.64M+46.3%
See all 791 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MRNA

Earnings Per Share

13fpro.ai/company/MRNA

Loading ratio trend…

MRNA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Moderna, Inc.'s annual filings on SEC EDGAR.

Moderna, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.9B$-2.8B-158.1%
FY 2024$3.2B$-3.6B-121.9%
FY 2023$6.8B$-4.7B-61.9%
FY 2022$19.3B$8.4B48.9%
FY 2021$18.5B$12.2B72.0%
FY 2020$803.0M$-747.0M-95.0%
Source: MRNA filings on SEC EDGAR →

Companies similar to MRNA

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

MRNA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in MRNA

13 transactions in MRNA reported by 5 members of Congress under the STOCK Act, most recent trade Sep 24, 2026. Reported transactions, not recommendations.

All Congress stock trades →

About Moderna, Inc. (MRNA): stock profile, AI score and financials

Moderna, Inc. (MRNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRNA at 19.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,757 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.8) and profitability (6.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Moderna, Inc. reports quarterly revenue of $145.0M, net income of $-782.0M, free cash flow of $-563.0M. Top institutional holders of MRNA by reported 13-F value include FMR, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRNA trades on the Nasdaq exchange and files with the SEC under CIK 1682852. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moderna, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1682852 →